4-(2-Butylamino)-2,7-dimethyl-8-(2-met hyl-6-methoxypyrid-3-yl) pyrazolo- [1,5-a]-1,3,5triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands

Details for Australian Patent Application No. 2002245605 (hide)

International Classifications

Event Publications

20 March 2003 Application Open to Public Inspection

Published as AU-B-2002245605

2 February 2006 Application Accepted

Published as AU-B-2002245605

1 June 2006 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

This application lapsed under reg. 22.2I(2). This application has been accepted or advertised accepted. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

15 June 2006 Section 223 Application Allowed

Bristol-Myers Squibb Pharma Company The time in which to pay the acceptance fee has been extended to 02 Jun 2006. Address for service in Australia - Callinan Lawrie 711 High Street Kew VIC 3101

17 August 2006 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.